South Coast Chamber study finds immigration activity is hurting local businesses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Gallegly and CLU settle former congressman’s breach of contract suit
Editor’s note: This story was originally published on Sept. 8 and updated on Sept. 11 to include more details on the settlement. A settlement has ended a nearly four-year legal battle between former congressman Elton Gallegly and California Lutheran University over a public service center named after him. The parties announced Sept. 8 that they Read More →
Reach secures $9.5M to accelerate Vandenberg growth
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen to invest $600M in new science and innovation center
Biotech giant Amgen on Sept. 2 announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks. The center is designed to bring together researchers, engineers, and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most Read More →
MannKind diversifies pipeline with $360M buy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind expands pipeline with $350M acquisition
Westlake Village-based MannKind Corporation is expanding its pipeline by acquiring scPharmaceuticals, a Massachusetts-based biotech company that specializes in cardiorenal medicine, for $360 million, or $5.35 per share. Announced before the markets opened Aug. 25, MannKind shares ticked up about 1% in pre-market trading. Shares ultimately settled at $3.90 on Aug. 25, about 3.1% down. Shares Read More →
